Loading
A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, now recruiting.
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas is a phase 3 interventional study registered as NCT07463235 by University of Sao Paulo General Hospital, with 70 participants planned, started 2026-03-04 and due to reach its primary completion in 2027-08-20. Interventions recorded: Cabergoline, Cabergoline. Conditions recorded: Prolactinoma, Prolactin Excess.
Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.